The MARIPOSA‐2 study demonstrated a PFS benefit for amivantamab combined with chemotherapy and/or lazertinib in patients with EGFR‐mutated NSCLC who had progressed on osimertinib.41 Here, EGFR is linked to non-small cell lung carcinoma.